Orthobiologics

lt;p>Giuseppe Filardo is the chief research advisor at the Rizzoli Orthopedic Institute for Translational and Applied Orthopedics, Bologna, and head of clinical research at the Ospedale Regionale of Lugano, Switzerland. His clinical research activities focus on the study of orthobiologics for the musculoskeletal system, particularly the development of minimally invasive treatments and the identification of the potential, indications and limits of the newly emerging regenerative approaches.

Bert Mandelbaum is double board certified in orthopedic surgery and orthopedic sports medicine. He received his MD degree from Washington University in St. Louis, then completed his residency at Johns Hopkins Hospital. He is widely recognized as one of the world's foremost experts in soccer injury. He has served as a head team physician on the men's and women's teams for multiple World Cups and Olympic Games.

George Muschler has become a respected expert in reconstructive surgery for arthritis, failed joint replacements, treatment of fractures and limb deformities. He is recognized internationally as a leader in skeletal reconstruction, bone regeneration, and fracture repair. A member of the Cleveland Clinic Taussig Cancer, he is a pioneer in the development of collaborative interdisciplinary programs and research teams in the area of tissue engineering and regenerative medicine.

Scott Rodeo is a clinician scientist at the Hospital for Special Surgery (HSS), with appointments in the Department of Orthopedics and the Research Department. He is a Professor of Orthopedic Surgery at Weill Cornell Medical College and Co-Chief Emeritus of the Sports Medicine Service at the Hospital for Special Surgery. He specializes in sports medicine injuries of the knee, shoulder, ankle and elbow and performs arthritis surgery on the knee and shoulder, including joint replacement surgery.

Norimasa Nakamura is a Professor at the Institute for Medical Science in Sports at Osaka Health Science University and the Global Center for the Medical Engineering and Informatics at Osaka University. He is also an orthopedic surgeon at the Osaka University Hospital, specializing in arthroscopic surgery and sports medicine. His research focuses on joint-tissue repair, particularly the regeneration of cartilage, ligament, and meniscus. He has published over 150 peer reviewed scientific papers.

I. Injectable OrthoBiologics: Formulations and Rationale 1. Bone marrow-derived cultured stromal cells and Bone Marrow Concentrate.- 2. Adipose-derived cultured stromal cells and Stromal Vascular Fraction from adipose tissue.- 3. Synovial-derived cultured stromal cells.- 4. Amniotic, Placenta, and Umbilical cord-derived cultured stromal cells.- 5. Allogeneic cells: pros and cons.- 6. Steroid hormones.- 7. Cytokines, chemokines, alpha-2-macroglobulin, growth factors.- 8. Platelet-rich plasma: leucocyte-rich, leukocyte-poor, autologous conditioned serum, autologous protein    solution.- 9. Amniotic tissue extract, placenta tissue extract.- 10. Extracellular vesicles (exosomes).- II. Injectable OrthoBiolologics: evaluation methods and results based on pathology and anatomy.- 11. Rotator cuff tendinopathy: cell therapy.- 12. Rotator cuff tendinopathy: biologics.- 13. Tennis elbow: cell therapy.- 14. Tennis elbow: cell therapy biologics.- 15. Patellar tendinopathy: cell therapy.- 16. Patellar tendinopathy: biologics.- 17. Achilles tendinopathy: cell therapy.- 18. Achilles tendinopathy: biologics.- 19. Plantar Fasciitis: cell therapy.- 20.  Plantar Fasciitis: biologics.- 21. Ligament lesions: cell therapy.- 22. Ligament lesions: biologics.- 23. Meniscal lesions: cell therapy.- 24. Meniscal lesions: biologics.- 25. Muscle lesions: cell therapy.- 26. Muscle lesions: biologics.- 27. Fractures (incl. Nonunions): cell therapy.- 28. Fractures (incl. Nonunions): biologics.- 29. Cartilage lesions and Osteoarthritis of the knee: cell therapy.- 30. Cartilage lesions and Osteoarthritis of the knee: biologics.- 31.    Cartilage lesions and Osteoarthritis of the hip and ankle: cell therapy.- 32. Cartilage lesions and Osteoarthritis of the hip and ankle: biologics.- III. Future directions 33. Pluripotent stem cells: Embryonic/Fetal stem cells and induced pluripotent stem (iPS) cells.- 34. Gene therapy.- 35.Stimulation of the intrinsic stromal cell niche.- 36 Conclusions.